Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Mark Gurney, Ismahene Chekkaf, Rong He, David S. Viswanatha, Patricia Greipp, Abhishek A. Mangaonkar, Kebede Begna, Naseema Gangat, Mrinal M. Patnaik, Mark R. Litzow, James M. Foran, Talha Badar, Mithun V. Shah, Hassan B. Alkhateeb, Aref Al-Kali

Blood (2022) 140 (Supplement 1): 6912–6914.

DOI: https://doi.org/10.1182/blood-2022-170641

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

DOI: https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

DOI: https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Clifford M. Csizmar, Antoine N. Saliba, Mark R. Litzow, Naseema Gangat, Aref Al-Kali, James M. Foran, William J. Hogan, Jeanne M. Palmer, Abhishek A. Mangaonkar, Kirsten McCullough, Ayalew Tefferi, Hassan B. Alkhateeb, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 12238–12240.

DOI: https://doi.org/10.1182/blood-2022-165470

Published: 2022

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

DOI: https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stephane De Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen M. Pettit, Stephen A Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 153–156.

DOI: https://doi.org/10.1182/blood-2022-167412

Published: 2022

Journal Articles

Prevalence of Vitamin C Deficiency and Bleeding at a Tertiary Care Center: Mayo Clinic Florida (MCF) Experience

ErinMarie O. Kimbrough, Ariana Mooradian, Michael G. Heckman, Zhongwei Peng, Emily B. Butts, Denise A. Gococo-Benore, Zaid Abdel Rahman, Ewa Wysokinska, Gretchen Schaef Johns, James M. Foran

Blood (2022) 140 (Supplement 1): 1420–1421.

DOI: https://doi.org/10.1182/blood-2022-170199

Published: 2022

Journal Articles

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

Stephanie L. Pritzl, Talha Badar, Alejandro Ferrer, Terra Lasho, Christy Finke, Abhishek A. Mangaonkar, Kristen McCullough, Naseema Gangat, Jenna A. Fernandez, Aref Al-Kali, David S. Viswanatha, Rong He, James M. Foran, Mrinal M. Patnaik

Blood (2022) 140 (Supplement 1): 11408–11409.

DOI: https://doi.org/10.1182/blood-2022-166794

Published: 2022

Journal Articles

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Anand P. Jillella, Sandra J. Lee, Jessica K. Altman, Selina M. Luger, Martin S. Tallman, James M. Foran, Lisa Y. Law, Locke J. Bryan, Abdallah Abou Zahr, Kebede Begna, Alexander Perl, Joseph Vadakara, Federico Sanchez, Raymond C. Bergan, Michael J. Fisch, Ruth C. Carlos, Lynne I. Wagner, Mark R. Litzow, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 1011–1013.

DOI: https://doi.org/10.1182/blood-2022-163436

Published: 2022

Journal Articles

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3 -Mutated Acute Myeloid Leukemia (AML)

Ahmad Ghorab, Mark R. Litzow, Naseema Gangat, Aref Al-Kali, Mithun V. Shah, Hemant S. Murthy, Ayalew Tefferi, Hassan B. Alkhateeb, Kebede Begna, Mrinal M. Patnaik, James M. Foran, Talha Badar

Blood (2022) 140 (Supplement 1): 9019–9020.

DOI: https://doi.org/10.1182/blood-2022-168303

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

DOI: https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

DOI: https://doi.org/10.1182/blood-2022-163518

Published: 2022

Journal Articles

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 12353–12354.

DOI: https://doi.org/10.1182/blood-2022-155561

Published: 2022

Journal Articles

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Naseema Gangat, Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al-Kali, Mrinal M.M. Patnaik, Mark R. Litzow, William J. Hogan, Abhishek A. Mangaonkar, Hassan B. Alkhateeb, Mithun V. Shah, Michelle A Elliott, James M. Foran, Talha Badar, Jeanne M. Palmer, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9675–9676.

DOI: https://doi.org/10.1182/blood-2022-163485

Published: 2022

Journal Articles

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Razan Mohty, Yenny Moreno Vanegas, Michael G. Heckman, Hassan B. Alkhateeb, Alexander P. Hochwald, William J. Hogan, Mohamed A. Kharfan-Dabaja, Rhett P. Ketterling, Nandita Khera, Mark R. Litzow, Abhishek A. Mangaonkar, Hemant S. Murthy, Jeanne M. Palmer, Mithun V. Shah, Lisa Z. Sproat, David S. Viswanatha, James M. Foran

Blood (2022) 140 (Supplement 1): 4863–4864.

DOI: https://doi.org/10.1182/blood-2022-168053

Published: 2022

Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 9070–9073.

DOI: https://doi.org/10.1182/blood-2022-166715

Published: 2022

Journal Articles

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Ayalew Tefferi, Christopher L Brooks, Guillermo Garcia-Manero, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 538.

DOI: https://doi.org/10.1182/blood-2021-147827

Published: 2021

Journal Articles

Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)

James M. Foran, Michael G. Heckman, Yesesri Cherukuri, Mikolaj Wieczorek, Zaid Abdel Rahman, Liuyan Jiang, Hemant S. Murthy, Laura Finn, Talha Badar, Lisa Z. Sproat, Yanyan Lou, James R. Cerhan, Yan Asmann

Blood (2021) 138 (Supplement 1): 3437.

DOI: https://doi.org/10.1182/blood-2021-151233

Published: 2021

Journal Articles

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Talha Badar, Ahmad Nanaa, Rong He, Aref Al-Kali, David S. Viswanatha, Emily Godsey, Lisa Z. Sproat, Mohamed A. Kharfan-Dabaja, Mrinal M. Patnaik, Hassan B. Alkhateeb, Mark R. Litzow, James M. Foran

Blood (2021) 138 (Supplement 1): 3693.

DOI: https://doi.org/10.1182/blood-2021-145115

Published: 2021

Journal Articles

Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies

Ahmad Ghorab, Aref Al-Kali, Michelle A. Elliot, Mithun V. Shah, Jeanne M. Palmer, Hemant S. Murthy, Mohamed A. Kharfan-Dabaja, Mark R. Litzow, James M. Foran, Talha Badar

Blood (2021) 138 (Supplement 1): 3688.

DOI: https://doi.org/10.1182/blood-2021-150626

Published: 2021

NARROW

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prevalence of Vitamin C Deficiency and Bleeding at a Tertiary Care Center: Mayo Clinic Florida (MCF) Experience

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3 -Mutated Acute Myeloid Leukemia (AML)

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only